Objective To identify and screen lactic acid bacteria (LAB) strains with antagonistic activity against Helicobacter pylori, addressing the increasing antibiotic resistance and declining H. pylori eradication rates.Methods LAB strains with anti-H. pylori activity were screened in vitro. The safety and probiotic properties of the selected strain were investigated, and its efficacy in alleviating H. pylori infection was validated via anti-inflammatory assays using gastric adenocarcinoma cell lines.Results The selected strain exhibited a clear inhibition zone against H. pylori with a diameter of 15.44 mm and a co-aggregation rate of 32.84%. Genomic annotation and antimicrobial susceptibility testing indicated a high safety profile. Cell inflammation assays demonstrated that the strain could reduce IL-8 secretion induced by the model by up to 78.18%.Conclusion The selected LAB strain effectively inhibits H. pylori growth and alleviates gastric inflammation, combining multiple probiotic characteristics with low pathogenic risk, providing a new probiotic candidate for combating H. pylori-associated gastrointestinal diseases.